The REPRIEVE trial suggests that primary cardiovascular disease (CVD) prevention could be considered among people with HIV at low CVD risk. We found cisgender women with low/moderate and high CVD risk are less likely to receive statins than cisgender men. Efforts are needed to guarantee equal access to statin-based CVD prevention.
Keywords: Cardiovascular prevention; gender disparities; people with HIV; prescription; statin.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.